SHR-1701
Based on 1 Customer Validation
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.77%
- CAS 番号: 2891860-17-4
- 分子式: HS
- 分子量:174.61 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
体外実験
SHR-1701 (10 μg/mL) can inhibit TGF-β signaling pathway, activate PI3K/Akt/Erk signaling pathway, rescue lymphocytes and restore the anti-tumor function of peripheral blood CD8+ T cells in patients with lung cancer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human PD-L1/B7-H1 Protein (ECD, His Tag) can bind SHR-1701. The EC50 for this effect is 0.42 ng/mL.
化学情報
-
CAS 番号 2891860-17-4
-
性状 Liquid
-
分子量 174.61 kDa
-
分子式 HS
-
Color Colorless to light yellow
-
SMILES
S[R1701]
-
別名
Retlirafusp alfa
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)